Teachers Retirement System of The State of Kentucky grew its position in Alkermes plc (NASDAQ:ALKS – Free Report) by 14.9% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 89,534 shares of the company’s stock after buying an additional 11,606 shares during the quarter. Teachers Retirement System of The State of Kentucky’s holdings in Alkermes were worth $3,628,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in ALKS. Root Financial Partners LLC purchased a new stake in shares of Alkermes during the third quarter worth approximately $25,000. Ameritas Advisory Services LLC acquired a new position in Alkermes in the 2nd quarter valued at $39,000. Allworth Financial LP raised its stake in Alkermes by 77.4% in the 3rd quarter. Allworth Financial LP now owns 958 shares of the company’s stock valued at $39,000 after purchasing an additional 418 shares during the last quarter. Versant Capital Management Inc raised its stake in Alkermes by 33.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,445 shares of the company’s stock valued at $76,000 after purchasing an additional 366 shares during the last quarter. Finally, Harbor Investment Advisory LLC purchased a new position in Alkermes in the 2nd quarter valued at $82,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on ALKS. Truist Financial began coverage on shares of Alkermes in a research note on Friday, October 16th. They set a “buy” rating and a $55.00 target price on the stock. JPMorgan Chase & Co. increased their target price on shares of Alkermes from $60.00 to $61.00 and gave the company a “neutral” rating in a research report on Wednesday, July 29th. Mizuho upgraded shares of Alkermes to a “strong-buy” rating in a research report on Wednesday, September 16th. The Goldman Sachs Group assumed coverage on shares of Alkermes in a research note on Thursday, September 24th. They issued a “neutral” rating and a $50.00 price target on the stock. Finally, Robert W. Baird set a $61.00 price target on shares of Alkermes in a research report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $55.73.
Insider Buying and Selling at Alkermes
In other Alkermes news, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $46.99, for a total value of $422,910.00. Following the sale, the executive vice president owned 65,389 shares in the company, valued at $3,072,629.11. The trade was a 12.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Gaffin sold 2,035 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $46.17, for a total value of $93,955.95. Following the completion of the transaction, the executive vice president directly owned 219,353 shares in the company, valued at approximately $10,127,528.01. This trade represents a 0.92% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 15,103 shares of company stock valued at $697,973. 4.59% of the stock is owned by insiders.
Alkermes Stock Up 3.1%
Shares of NASDAQ ALKS opened at $46.85 on Thursday. The company has a market capitalization of $7.87 billion, a P/E ratio of -2,341.33 and a beta of 0.32. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.42 and a quick ratio of 2.02. The company has a 50 day simple moving average of $43.71 and a 200-day simple moving average of $41.31. Alkermes plc has a 1 year low of $27.00 and a 1 year high of $55.67.
Alkermes (NASDAQ:ALKS – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.17. The firm had revenue of $480.13 million for the quarter, compared to analysts’ expectations of $463.48 million. Alkermes had a positive return on equity of 0.40% and a negative net margin of 0.02%. The firm’s quarterly revenue was up 21.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.49 earnings per share. On average, equities research analysts predict that Alkermes plc will post -0.52 earnings per share for the current year.
About Alkermes
Alkermes plc is a biopharmaceutical company focused on developing and commercializing medicines for neuroscience-related conditions, including serious mental illness and addiction. Founded in 1987, the company has operations in the United States and Ireland, with its corporate headquarters in Dublin and major U.S. operations in Massachusetts. Its marketed medicines include Vivitrol, an extended-release injectable formulation of naltrexone used to treat alcohol dependence and to prevent relapse to opioid dependence after detoxification; Aristada, an injectable treatment for schizophrenia in adults; and Lybalvi, a medicine for schizophrenia and bipolar I disorder in adults.
Featured Stories
- Five stocks we like better than Alkermes
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Want to see what other hedge funds are holding ALKS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alkermes plc (NASDAQ:ALKS – Free Report).
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.
